NeoSpect

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
18-11-2010
Tabia za bidhaa Tabia za bidhaa (SPC)
18-11-2010

Viambatanisho vya kazi:

depreotide trifluoroacetate

Inapatikana kutoka:

CIS bio international

ATC kanuni:

V09IA05

INN (Jina la Kimataifa):

depreotide

Kundi la matibabu:

Diagnostic radiopharmaceuticals

Eneo la matibabu:

Radionuclide Imaging

Matibabu dalili:

This medicinal product is for diagnostic use only.For scintigraphic imaging of suspected malignant tumours in the lung after initial detection, incombination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.

Bidhaa muhtasari:

Revision: 10

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

2000-11-29

Taarifa za kipeperushi

                                Medicinal product no longer authorised
18
B. PACKAGE LEAFLET
Medicinal product no longer authorised
19
PACKAGE LEAFLET: INFORMATION FOR THE USER
NEOSPECT 47 MICROGRAMS. KIT FOR RADIOPHARMACEUTICAL PREPARATION
Depreotide
PLEASE READ THIS LEAFLET CAREFULLY. IT TELLS YOU ABOUT YOUR MEDICINE.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor.
-
If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet,
please tell your doctor.
IN THIS LEAFLET:
1.
What NeoSpect
is and what it is used for.
2.
Before you use
NeoSpect.
3.
How to use
NeoSpect.
4.
Possible side effects.
5.
How to store
NeoSpect.
6.
Further information.
1.
WHAT NEOSPECT
IS AND WHAT IT IS USED FOR
PRODUCT TYPE
NeoSpect is a radiopharmaceutical product used for diagnostic
purposes. A diagnostic
radiopharmaceutical is a product which, when injected, temporarily
collects in a particular part of the
body (for example a tumour). Because the substance contains a small
amount of radioactivity it can be
detected from outside the body using special cameras, and a picture,
known as a scan, can be taken.
This scan will show exactly the distribution of the radioactivity
within the body. This can give the
doctor valuable information such as the location of a tumour.
WHAT NEOSPECT
IS USED FOR
NeoSpect
is for diagnostic use only. NeoSpect is used to provide pictures which
show the location of
suspected malignant cancer tissue (a tumour) in the lung. When
injected, the radiolabelled compound
binds to malignant cancer tissue. Your doctor will then take a picture
(scan) of your lungs using a
special camera. The area where the radioactive compound is collected,
will light up on the picture and
give information on the location of the tumour. The evaluation also
includes examinations by CT-scan
or chest X-ray.
2.
BEFORE YOU USE NEOSPECT
DO NOT USE
NEOSPECT
-
if you are allergic (hypersensitive) to depreotide or any of the other
ingredients of NeoSpect or
to the radioactive techneti
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
NeoSpect
_ _
47 micrograms, kit for radiopharmaceutical preparation.
2.
QUALITATIVE
AND
QUANTITATIVE
COMPOSITION
Each vial contains 47 micrograms depreotide as depreotide
trifluoroacetate.
For a full list of excipients, see section 6.1
To be reconstituted with sodium pertechnetate (
99m
Tc) solution for injection (not included in this kit).
3.
PHARMACEUTICAL
FORM
Kit for radiopharmaceutical preparation. White powder for solution for
injection.
4.
CLINICAL
PARTICULARS
4.1
THERAPEUTIC INDICATIONS
This medicinal product is for diagnostic use only.
For scintigraphic imaging of suspected malignant tumours in the lung
after initial detection, in
combination with CT scan or chest X-ray, in patients with solitary
pulmonary nodules.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The medicinal product is for hospital use or in designated Nuclear
Medicine Facilities only, by persons
experienced in radioisotope diagnostic imaging.
Instructions for reconstitution, handling and disposal are given in
section 12.
After reconstitution with sodium pertechnetate (
99m
Tc) solution for injection,
99m
Tc-depreotide
is
formed.
99m
Tc-depreotide is administered intravenously in a single dose. The
solution may be diluted with
sodium chloride 0.9% w/v solution for injection for more convenient
injection. SPECT images (Single
Photon Emission Computed Tomography) obtained between 2 and 4 hours
following
99m
Tc-depreotide
injection are required for optimal image interpretation.
DOSAGE FOR ADULTS
The recommended dosage is approximately 47 micrograms depreotide (one
vial) labelled with
555-740 MBq of technetium-99m.
DOSAGE FOR ELDERLY (>65 YEARS)
Experience from clinical trials indicates that no dose adjustment is
required.
CHILDREN
99m
Tc-depreotide is not recommended for use in patients below the age of
18 as data are not available
for this age group.
RENAL IMPAIRMENT
No dose adjustment is 
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kibulgaria 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kihispania 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kicheki 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kidenmaki 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kijerumani 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kiestonia 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kigiriki 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kifaransa 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kiitaliano 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kilatvia 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kilithuania 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kihungari 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kimalta 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kiholanzi 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kipolandi 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kireno 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kiromania 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kislovakia 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kislovenia 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kifinlandi 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 19-11-2010
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 18-11-2010
Tabia za bidhaa Tabia za bidhaa Kiswidi 18-11-2010
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 19-11-2010

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati